Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
Palisade Bio (NASDAQ:PALI) has appointed Dr. Emil Chuang to its Board of Directors. Dr. Chuang brings nearly 25 years of pharmaceutical and clinical experience in gastroenterology, with expertise spanning from preclinical research through Phase 1-4 clinical development.
Dr. Chuang's notable achievements include contributions to two successful regulatory approvals: infliximab for pediatric Crohn's disease and lorcaserin for morbid obesity. Currently serving as Chief Medical Officer at Intrinsic Medicine, he has previously held leadership positions at Nestlé Health Science, Takeda, and Progenity. His expertise will support Palisade Bio's clinical programs in Fibrostenotic Crohn's Disease and Ulcerative Colitis, particularly focusing on the development of PALI-2108.
Palisade Bio (NASDAQ:PALI) ha nominato Dr. Emil Chuang nel suo Consiglio di Amministrazione. Il Dr. Chuang porta con sé quasi 25 anni di esperienza nel settore farmaceutico e clinico in gastroenterologia, con competenze che spaziano dalla ricerca preclinica fino allo sviluppo clinico di Fasi 1-4.
Tra i suoi successi più importanti vi sono i contributi a due approvazioni regolatorie di rilievo: infliximab per il morbo di Crohn pediatrico e lorcaserin per l'obesità grave. Attualmente Chief Medical Officer presso Intrinsic Medicine, ha ricoperto in precedenza ruoli di leadership in Nestlé Health Science, Takeda e Progenity. La sua esperienza sosterrà i programmi clinici di Palisade Bio per la malattia di Crohn fibrostenotica e la colite ulcerosa, con particolare attenzione allo sviluppo di PALI-2108.
Palisade Bio (NASDAQ:PALI) ha designado a Dr. Emil Chuang en su Junta Directiva. El Dr. Chuang aporta casi 25 años de experiencia farmacéutica y clínica en gastroenterología, con conocimientos que abarcan desde la investigación preclínica hasta el desarrollo clínico en fases 1-4.
Entre sus logros destacados se incluyen contribuciones a dos aprobaciones regulatorias exitosas: infliximab para la enfermedad de Crohn pediátrica y lorcaserina para la obesidad mórbida. Actualmente se desempeña como Director Médico en Intrinsic Medicine y anteriormente ocupó cargos de liderazgo en Nestlé Health Science, Takeda y Progenity. Su experiencia apoyará los programas clínicos de Palisade Bio en enfermedad de Crohn fibroestenótica y colitis ulcerosa, con un enfoque especial en el desarrollo de PALI-2108.
Palisade Bio (NASDAQ:PALI)는 Emil Chuang 박사를 이사회에 임명했습니다. Chuang 박사는 위장병학 분야에서 거의 25년간의 제약 및 임상 경험을 보유하고 있으며, 전임상 연구부터 1상에서 4상 임상 개발까지 폭넓은 전문 지식을 갖추고 있습니다.
그의 주요 성과로는 소아 크론병 치료를 위한 인플릭시맙과 병적 비만 치료를 위한 로르카세린의 두 건의 규제 승인에 기여한 점이 있습니다. 현재 Intrinsic Medicine의 최고 의료 책임자로 재직 중이며, 이전에는 Nestlé Health Science, Takeda, Progenity에서 리더십 직책을 맡았습니다. 그의 전문성은 특히 PALI-2108 개발에 중점을 두어 섬유협착성 크론병 및 궤양성 대장염에 대한 Palisade Bio의 임상 프로그램을 지원할 것입니다.
Palisade Bio (NASDAQ:PALI) a nommé Dr Emil Chuang à son conseil d'administration. Le Dr Chuang apporte près de 25 ans d'expérience pharmaceutique et clinique en gastro-entérologie, avec une expertise allant de la recherche préclinique au développement clinique de phases 1 à 4.
Parmi ses réalisations notables figurent sa contribution à deux approbations réglementaires réussies : l'infliximab pour la maladie de Crohn pédiatrique et le lorcaserin pour l'obésité morbide. Actuellement directeur médical chez Intrinsic Medicine, il a auparavant occupé des postes de direction chez Nestlé Health Science, Takeda et Progenity. Son expertise soutiendra les programmes cliniques de Palisade Bio dans la maladie de Crohn fibro-sténotique et la colite ulcéreuse, en se concentrant particulièrement sur le développement de PALI-2108.
Palisade Bio (NASDAQ:PALI) hat Dr. Emil Chuang in seinen Vorstand berufen. Dr. Chuang bringt nahezu 25 Jahre pharmazeutische und klinische Erfahrung im Bereich Gastroenterologie mit, mit Fachwissen von der präklinischen Forschung bis hin zur klinischen Entwicklung in den Phasen 1 bis 4.
Zu seinen bemerkenswerten Erfolgen zählen Beiträge zu zwei erfolgreichen Zulassungen: Infliximab für pädiatrische Morbus Crohn und Lorcaserin bei morbider Adipositas. Derzeit ist er Chief Medical Officer bei Intrinsic Medicine und hatte zuvor Führungspositionen bei Nestlé Health Science, Takeda und Progenity inne. Seine Expertise wird die klinischen Programme von Palisade Bio bei fibrostenotischer Morbus Crohn und Colitis ulcerosa unterstützen, insbesondere bei der Entwicklung von PALI-2108.
- Addition of experienced board member with 25 years of pharmaceutical and clinical expertise
- Dr. Chuang's track record includes two successful regulatory approvals (NDA/sBLA)
- Specific expertise in inflammatory bowel diseases (IBD) aligns with company's clinical focus
- None.
Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis
Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of Directors.
Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nutrition, and diagnostics. His expertise spans from preclinical translational medicine through Phase 1-4 clinical development. Notably, his leadership has contributed to multiple drug development programs, including two successful regulatory approvals (NDA/sBLA): infliximab for pediatric Crohn’s disease and lorcaserin for morbid obesity.
Following a successful academic career as an Assistant Professor at both Duke University and the University of Pennsylvania, Dr. Chuang transitioned into the pharmaceutical industry, where he has earned a reputation for simplifying complex challenges into actionable development strategies. His work includes significant contributions to programs targeting inflammatory bowel diseases (IBD), including infliximab and vedolizumab.
“We are very pleased to welcome Emil to our Board of Directors. His extensive clinical development experience and deep understanding of IBD will provide valuable insight as we continue to execute our clinical programs. We look forward to leveraging his knowledge to advance our pipeline,” commented JD Finley, Chief Executive Officer of Palisade Bio.
“I am excited to work with the Palisade team to help unlock the full value of its pipeline and bring meaningful solutions to patients where there remain unmet medical needs,” added Dr. Chuang. “The progress made to date, as well as the data demonstrated by PALI-2108 for addressing Fibrostenotic Crohn’s Disease and Ulcerative Colitis is very compelling, and I look forward to helping advance these important programs.”
Dr. Chuang currently serves as the Chief Medical Officer at Intrinsic Medicine, a privately held biotechnology company. He also leads Chuang Global Consulting, his independent advisory firm. His prior leadership roles include Head of GI Clinical Development for Nestlé Health Science, Head of GI Translational Research and Early Clinical at Takeda, and Head of GI Precision Medicine at Progenity. Over the course of his career, Dr. Chuang has authored more than 80 peer-reviewed publications, abstracts, and book chapters.
He received his medical degree (MB BS) from the University of Sydney, Australia and completed his pediatrics specialty training (FRACP) in Australia before moving to the United States, where he completed subspecialty training in both pediatric gastroenterology and nutrition.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study and indications and anticipated benefits of PALI-2108. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the timing and success of preclinical studies and clinical trials conducted by the Company; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; the Company’s need to raise significant additional funds to continue its plans and operations; and other factors that are described in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
Attachment
FAQ
Who is Dr. Emil Chuang and why did Palisade Bio (PALI) appoint him to the board?
What are Dr. Emil Chuang's major achievements in drug development?
What is PALI-2108 and what is its purpose?
What is Dr. Emil Chuang's current role besides joining Palisade Bio's board?
What experience does Dr. Chuang bring to Palisade Bio (PALI) in IBD treatment?
